Physician profile
Leon Curtis Chen
NPI 1588193916
$5,043.72
in general payments reported to CMS, 2019-2025
33 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $355 · 2021: $664 · 2022: $787 · 2023: $946 · 2024: $1,074 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,169 · Education: $50.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.34 |
| Education | $50.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.57 | 2020-2025 | Jardiance |
| Abbvie INC. | $485.68 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $401.79 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $352.29 | 2020-2024 | Airsupra, Farxiga |
| Abbott Laboratories | $342.87 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $306.98 | 2020-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $289.39 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $197.95 | 2022-2025 | Quviviq, Quviviq |
| Glaxosmithkline, LLC. | $170.54 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $168.94 | 2022-2023 | Vyepti |
| Pfizer INC. | $158.94 | 2021-2025 | |
| Antares Pharma, INC. | $155.74 | 2020-2025 | Xyosted |
| Exact Sciences Corporation | $151.68 | 2023-2025 | Cologuard Collection Kit |
| Medicure Pharma INC. | $131.99 | 2020-2024 | Zypitamag |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.63 | 2020-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $123.94 | 2021-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $122.80 | 2020-2023 | Steglatro |
| Currax Pharmaceuticals LLC | $122.46 | 2022-2025 | Nexletol, Contrave, Onzetra Xsail |
| Genentech USA, INC. | $119.00 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $79.17 | 2023 | Spravato |
| Corcept Therapeutics | $66.32 | 2024-2025 | Korlym |
| Sumitomo Pharma America, INC. | $62.31 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $58.25 | 2022-2025 | |
| Amarin Pharma, INC. | $56.57 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.22 | 2022 | |
| Phathom Pharmaceuticals, INC. | $44.39 | 2025 | Voquezna |
| Allergan, INC. | $27.11 | 2020 | |
| Optinose US, INC. | $21.12 | 2024 | |
| Arbor Pharmaceuticals, INC. | $18.18 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.75 | 2021 | |
| Agios Pharmaceuticals, INC. | $16.15 | 2024 | |
| Acerus Pharmaceuticals Corporation | $14.37 | 2021 | |
| Eisai INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.